This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weigelt, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weigelt, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2005, p. 2260-2266, Vol. 49, No. 6
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.6.2260-2266.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Linezolid versus Vancomycin in Treatment of Complicated Skin and Soft Tissue Infections

John Weigelt,1* Kamal Itani,2 Dennis Stevens,3 William Lau,4 Matthew Dryden,5 Charles Knirsch,6* the Linezolid CSSTI Study Group

Medical College of Wisconsin, Milwaukee, Wisconsin,1 Boston VA Health Care System and Boston University, Boston, Massachusetts,2 Veterans Affairs Medical Center, Boise, Idaho,3 St. Francis Medical Center West, Honolulu, Hawaii,4 Royal Hampshire County Hospital, Winchester, Hampshire, United Kingdom,5 Pfizer World Wide Medical, New York, New York6

Received 15 June 2004/ Returned for modification 8 November 2004/ Accepted 4 February 2005

Skin and soft tissue infections (SSTIs) are a common cause of morbidity in both the community and the hospital. An SSTI is classified as complicated if the infection has spread to the deeper soft tissues, if surgical intervention is necessary, or if the patient has a comorbid condition hindering treatment response (e.g., diabetes mellitus or human immunodeficiency virus). The purpose of this study was to compare linezolid to vancomycin in the treatment of suspected or proven methicillin-resistant gram-positive complicated SSTIs (CSSTIs) requiring hospitalization. This was a randomized, open-label, comparator-controlled, multicenter, multinational study that included patients with suspected or proven methicillin-resistant Staphylococcus aureus (MRSA) infections that involved substantial areas of skin or deeper soft tissues, such as cellulitis, abscesses, infected ulcers, or burns (<10% of total body surface area). Patients were randomized (1:1) to receive linezolid (600 mg) every 12 h either intravenously (i.v.) or orally or vancomycin (1 g) every 12 h i.v. In the intent-to-treat population, 92.2% and 88.5% of patients treated with linezolid and vancomycin, respectively, were clinically cured at the test-of-cure (TOC) visit (P = 0.057). Linezolid outcomes (124/140 patients or 88.6%) were superior to vancomycin outcomes (97/145 patients or 66.9%) at the TOC visit for patients with MRSA infections (P < 0.001). Drug-related adverse events were reported in similar numbers in both the linezolid and the vancomycin arms of the trial. The results of this study demonstrate that linezolid therapy is well tolerated, equivalent to vancomycin in treating CSSTIs, and superior to vancomycin in the treatment of CSSTIs due to MRSA.

* Corresponding author. Mailing address for Charles Knirsch: Pfizer Inc., 235 East 42nd Street, Mailstop 235/8/29, New York, NY 10017. Phone: (212) 733-4231. Fax: (212) 973-7379. E-mail: charles.knirsch{at}pfizer.com. Mailing address for John Weigelt: Department of Surgery, Medical College of Wisconsin, 200 W. Wisconsin Ave., Milwaukee, WI 53226. Phone: (414) 805-8636. Fax: (414) 805-8641. E-mail: jweigelt{at}mcw.edu.

Antimicrobial Agents and Chemotherapy, June 2005, p. 2260-2266, Vol. 49, No. 6
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.6.2260-2266.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • (2010). Management of community-associated MRSA. DTB 48: 14-19 [Abstract] [Full Text]  
  • Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., Grayson, M. L. (2010). Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications. Clin. Microbiol. Rev. 23: 99-139 [Abstract] [Full Text]  
  • Nguyen, H. M., Graber, C. J. (2010). Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer?. J Antimicrob Chemother 65: 24-36 [Abstract] [Full Text]  
  • Nicolau, D. P., Stein, G. E. (2010). Therapeutic Options for Diabetic Foot Infections: A Review with an Emphasis on Tissue Penetration Characteristics. J. Am. Podiatr. Med. Assoc. 100: 52-63 [Abstract] [Full Text]  
  • Bliziotis, I. A, Plessa, E., Peppas, G., Falagas, M. E (2010). Daptomycin Versus Other Antimicrobial Agents for the Treatment of Skin and Soft Tissue Infections: A Meta-Analysis. The Annals of Pharmacotherapy 44: 97-106 [Abstract] [Full Text]  
  • Singh, S. R., Bacon, A. E. III, Young, D. C., Couch, K. A. (2009). In Vitro 24-Hour Time-Kill Studies of Vancomycin and Linezolid in Combination versus Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53: 4495-4497 [Abstract] [Full Text]  
  • Elward, A. M., McAndrews, J. M., Young, V. L. (2009). Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus: Preventing Surgical Site Infections Following Plastic Surgery. Aesthetic Surgery Journal 29: 232-244 [Abstract] [Full Text]  
  • Gould, F. K., Brindle, R., Chadwick, P. R., Fraise, A. P., Hill, S., Nathwani, D., Ridgway, G. L., Spry, M. J., Warren, R. E., on behalf of the MRSA Working Party of the British, (2009). Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother 63: 849-861 [Abstract] [Full Text]  
  • Wargo, K. A., Eiland, E. H. III, Eiland, L. S. (2008). Management and Treatment Considerations for Infections Caused by Methicillin-Resistant Staphylococcus aureus. Journal of Pharmacy Practice 21: 324-336 [Abstract]  
  • Amsler, K. M., Davies, T. A., Shang, W., Jacobs, M. R., Bush, K. (2008). In Vitro Activity of Ceftobiprole against Pathogens from Two Phase 3 Clinical Trials of Complicated Skin and Skin Structure Infections. Antimicrob. Agents Chemother. 52: 3418-3423 [Abstract] [Full Text]  
  • Zoumalan, R. A., Rosenberg, D. B. (2008). Methicillin-Resistant Staphylococcus aureus-Positive Surgical Site Infections in Face-lift Surgery. Arch Facial Plast Surg 10: 116-123 [Abstract] [Full Text]  
  • Noel, G. J., Strauss, R. S., Amsler, K., Heep, M., Pypstra, R., Solomkin, J. S. (2008). Results of a Double-Blind, Randomized Trial of Ceftobiprole Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria. Antimicrob. Agents Chemother. 52: 37-44 [Abstract] [Full Text]  
  • Kohno, S., Yamaguchi, K., Aikawa, N., Sumiyama, Y., Odagiri, S., Aoki, N., Niki, Y., Watanabe, S., Furue, M., Ito, T., Croos-Dabrera, R., Tack, K. J. (2007). Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother 60: 1361-1369 [Abstract] [Full Text]  
  • Rajendran, P. M., Young, D., Maurer, T., Chambers, H., Perdreau-Remington, F., Ro, P., Harris, H. (2007). Randomized, Double-Blind, Placebo-Controlled Trial of Cephalexin for Treatment of Uncomplicated Skin Abscesses in a Population at Risk for Community-Acquired Methicillin-Resistant Staphylococcus aureus Infection. Antimicrob. Agents Chemother. 51: 4044-4048 [Abstract] [Full Text]  
  • Livermore, D. M., Warner, M., Mushtaq, S., North, S., Woodford, N. (2007). In Vitro Activity of the Oxazolidinone RWJ-416457 against Linezolid-Resistant and -Susceptible Staphylococci and Enterococci. Antimicrob. Agents Chemother. 51: 1112-1114 [Abstract] [Full Text]  
  • Maclayton, D. O, Hall II, R. G (2007). Pharmacologic Treatment Options for Nosocomial Pneumonia Involving Methicillin-Resistant Staphylococcus aureus. The Annals of Pharmacotherapy 41: 235-244 [Abstract] [Full Text]  
  • French, G. L. (2006). Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin. J Antimicrob Chemother 58: 1107-1117 [Abstract] [Full Text]  
  • Grau, S., Antonio, J. M.-d., Marin-Casino, M. (2006). Comment: Impact of Linezolid on Economic Outcomes and Determinants of Cost in a Clinical Trial Evaluating Patients with MRSA Complicated Skin and Soft-Tissue Infections. The Annals of Pharmacotherapy 40: 2280-2280 [Full Text]  
  • McKinnon, P. S, Sorensen, S. V, Liu, L. Z, Itani, K. M. (2006). Authors' Reply. The Annals of Pharmacotherapy 40: 2280-2281 [Full Text]  
  • Moran, G. J., Krishnadasan, A., Gorwitz, R. J., Fosheim, G. E., McDougal, L. K., Carey, R. B., Talan, D. A., the EMERGEncy ID Net Study Group, (2006). Methicillin-Resistant S. aureus Infections among Patients in the Emergency Department.. NEJM 355: 666-674 [Abstract] [Full Text]  
  • de Almeida, K. N.F., Bush, L. M. (2006). Treatment of community-acquired methicillin-resistant Staphylococcus aureus infection.. ANN INTERN MED 145: 231-232 [Full Text]  
  • McKinnon, P. S, Sorensen, S. V, Liu, L. Z, Itani, K. M. (2006). Impact of Linezolid on Economic Outcomes and Determinants of Cost in a Clinical Trial Evaluating Patients with MRSA Complicated Skin and Soft-Tissue Infections. The Annals of Pharmacotherapy 40: 1017-1023 [Abstract] [Full Text]  
  • Sabol, K. E, Echevarria, K. L, Lewis, J. S II (2006). Community-Associated Methicillin-Resistant Staphylococcus aureus: New Bug, Old Drugs. The Annals of Pharmacotherapy 40: 1125-1133 [Abstract] [Full Text]  
  • Kalil, A. C., Puumala, S., Stoner, J., Weigelt, J., Itani, K., Stevens, D., Knirsch, C. (2006). Is Linezolid Superior to Vancomycin for Complicated Skin and Soft Tissue Infections Due to Methicillin-Resistant Staphylococcus aureus?. Antimicrob. Agents Chemother. 50: 1910-1911 [Full Text]  
  • Healy, B., Freedman, A. (2006). Infections.. BMJ 332: 838-841 [Full Text]  
  • Pai, M. P, Mercier, R.-C., Allen, S. E (2006). Using Vancomycin Concentrations for Dosing Daptomycin in a Morbidly Obese Patient with Renal Insufficiency. The Annals of Pharmacotherapy 40: 553-558 [Abstract] [Full Text]  
  • Jones, R. N., Ross, J. E., Fritsche, T. R., Sader, H. S. (2006). Oxazolidinone susceptibility patterns in 2004: report from the Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother 57: 279-287 [Abstract] [Full Text]  
  • Howden, B. P., Charles, P. G. P., Johnson, P. D. R., Ward, P. B., Grayson, M. L., Weigelt, J. A., Itani, K., Stevens, D., Lau, W., Dryden, M., Knirsch, C. (2005). Improved Outcomes with Linezolid for Methicillin-Resistant Staphylococcus aureus Infections: Better Drug or Reduced Vancomycin Susceptibility?. Antimicrob. Agents Chemother. 49: 4816-4817 [Full Text]  
  • (2005). Linezolid vs. Vancomycin for Soft-Tissue Infections. JWatch Infect. Diseases 2005: 6-6 [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»